The maker of weight-loss and diabetes drugs has supercharged the Danish economy — but other businesses complain that’s left ...

Construction has already begun on the Ozempic-producer’s new Danish production facility and 40,000m² warehouse.

Novo Nordisk is set to invest $1.2 billion for a new facility in Odense, Denmark, to produce various product types for rare ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Eli Lilly and Novo Nordisk will kick off a massive shopping spree in 2025. The two obesity giants will be sitting on cash ...

Vermont now provides partial GLP-1 coverage for obesity: Among the obesity-indicated GLP-1s, Medicaid in Vermont covers just ...

Danish drugmaker Novo Nordisk (NVO) is investing $1.20 billion U.S. in a new facility that will produce medications to treat ...

The obesity treatment market is dominated by Eli Lilly and Novo Nordisk, making it challenging for Viking. Read why I ...

Not just drugs for obesity and diabetes. The Danish pharmaceutical giant differentiates itself in other sectors ...

The end of Novo Nordisk’s supply problems could bring new headaches for the rest of the pharmaceutical industry, which now ...

It’s likely to still be there at the end of the year, but by the time the final sales figures for 2024 are tallied up, Novo ...

Sermo queried more than 1,150 healthcare providers for the latest edition of its “Barometer” report and found that nearly 80% ...